Subsequently, to investigate whether SK-216 treatment inhibits tumor regrowth by inhibiting the proliferation of cells tolerant to EGFR-TKI, we compared tumor growth over a prolonged period between four groups: an osimertinib-treated group, an SK-216-treated group, an osimertinib + SK-216-treated group, and a vehicle-treated group. Here, EGFR is linked to neoplasm.